PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 19, 2026ESMO Open0 citationsOpen Access

154eP Real-world effectiveness and resource utilization of first-line pembrolizumab in NSCLC: A retrospective observational study (MOSAICO study)

View Full Paper
AUAntonio UngaroAzienda Ospedaliera S.Giuseppe MoscatiMCM. CalcagnoAzienda Ospedaliera S.Giuseppe MoscatiTGTiziana GuarinoAzienda Ospedaliera S.Giuseppe Moscati

Key Points

  • The study aims to evaluate the real-world effectiveness and cost-effectiveness of first-line pembrolizumab in treating metastatic NSCLC.
  • Retrospective observational study design
  • Analysis of long-term patient outcomes
  • Utilization of quality-adjusted life-years (QALYs) and disability-adjusted life-years (DALYs)
  • Evaluation of incremental cost-effectiveness ratios (ICERs)
  • Improved survival rates associated with pembrolizumab therapy
  • Demonstrated durable benefits in patient quality of life
  • Highlighting the high upfront costs compared to long-term value metrics

Abstract

Anti–PD-1/PD-L1 therapy has reshaped the therapeutic paradigm of metastatic NSCLC, improving survival and enabling durable benefit. However, the high upfront expenditure associated with immunotherapy has increased the need to frame real-world effectiveness within long-term value metrics, including quality-adjusted life-years (QALYs), disability-adjusted life-years (DALYs) and incremental cost-effectiveness ratios (ICERs), to better capture downstream gains in quality and quantity of life.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Ungaro et al. (2026) studied this question.

synapsesocial.com/papers/69bb9313496e729e62980db7https://doi.org/10.1016/j.esmoop.2026.106461
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1158eP Prognostic impact of the pan-immune-inflammation value in advanced non-small cell lung cancer treated with first-line pembrolizumab: A real-world cohort study2026
  2. 2156eP Integrated metabolomic and tumor microenvironment profiling identifies predictive biomarkers for immunotherapy response in advanced NSCLC2026
  3. 3155eP Real-world effectiveness of first-line nivolumab plus ipilimumab with chemotherapy in patients with non-small cell lung cancer with low PD-L1 tumor expression (Dutch NVALT-34 study)2026
  4. 4Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience2026
  5. 5Real World Safety and Outcome of First Line Pembrolizumab Monotherapy for Metastatic NSCLC with PDL-1 Expression ≥ 50%: A National Italian Multicentric Cohort (“PEMBROREAL” Study)2024 · 2 citations